2020 Q4 Form 10-Q Financial Statement
#000156459020049430 Filed on November 02, 2020
Income Statement
| Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.750M | $3.450M | $4.610M |
| YoY Change | -2.34% | -25.16% | 13.83% |
| % of Gross Profit | |||
| Research & Development | $3.550M | $4.640M | $9.674M |
| YoY Change | -87.55% | -52.04% | 15.59% |
| % of Gross Profit | |||
| Depreciation & Amortization | $10.00K | $0.00 | $0.00 |
| YoY Change | 0.0% | ||
| % of Gross Profit | |||
| Operating Expenses | $7.300M | $8.090M | $14.28M |
| YoY Change | -77.45% | -43.35% | 14.95% |
| Operating Profit | -$7.299M | -$8.090M | -$14.28M |
| YoY Change | -77.45% | -43.36% | 14.95% |
| Interest Expense | -$30.00K | -$20.00K | $320.0K |
| YoY Change | -115.0% | -106.25% | -8064.16% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$7.320M | -$8.110M | -$13.96M |
| YoY Change | -77.25% | -41.91% | 16.14% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$7.324M | -$8.113M | -$13.96M |
| YoY Change | -75.52% | -41.9% | 16.15% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.19 | -$0.36 | |
| Diluted Earnings Per Share | -$171.4K | -$0.19 | -$0.36 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 42.67M | 41.92M | 39.03M |
| Diluted Shares Outstanding | 41.92M | 39.03M |
Balance Sheet
| Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $25.40M | $32.50M | $59.90M |
| YoY Change | -44.66% | -45.74% | -38.63% |
| Cash & Equivalents | $25.36M | $32.52M | $37.91M |
| Short-Term Investments | $0.00 | $22.00M | |
| Other Short-Term Assets | $2.100M | $2.500M | $1.500M |
| YoY Change | 61.54% | 66.67% | -60.53% |
| Inventory | |||
| Prepaid Expenses | $1.983M | $1.377M | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $27.44M | $35.00M | $61.41M |
| YoY Change | -41.79% | -43.01% | -39.44% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $100.0K | $100.0K | $20.38K |
| YoY Change | 524.57% | 390.73% | |
| Goodwill | $14.87M | $14.87M | |
| YoY Change | 0.0% | ||
| Intangibles | $15.20M | $34.20M | |
| YoY Change | 0.0% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $14.81K | $0.00 | $14.81K |
| YoY Change | 0.0% | -100.0% | |
| Total Long-Term Assets | $30.19M | $30.20M | $49.40M |
| YoY Change | -0.58% | -38.87% | 0.62% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $27.44M | $35.00M | $61.41M |
| Total Long-Term Assets | $30.19M | $30.20M | $49.40M |
| Total Assets | $57.63M | $65.20M | $110.8M |
| YoY Change | -25.64% | -41.16% | -26.37% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $995.6K | $700.0K | $5.330M |
| YoY Change | -57.03% | -86.87% | 492.27% |
| Accrued Expenses | $2.200M | $4.700M | $4.600M |
| YoY Change | -48.84% | 2.17% | 53.33% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $3.160M | $5.400M | $9.896M |
| YoY Change | -52.33% | -45.43% | 153.74% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $41.30M | |
| YoY Change | -100.0% | 137218.79% | |
| Total Long-Term Liabilities | $0.00 | $0.00 | $41.30M |
| YoY Change | -100.0% | -100.0% | 137218.79% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $3.160M | $5.400M | $9.896M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $41.30M |
| Total Liabilities | $4.964M | $7.198M | $55.29M |
| YoY Change | -90.02% | -86.98% | 12.6% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$284.8M | -$277.5M | -$256.8M |
| YoY Change | -0.68% | 8.05% | |
| Common Stock | $337.5M | $335.5M | $312.3M |
| YoY Change | 7.29% | 7.41% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $52.66M | $58.02M | $55.53M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $57.63M | $65.22M | $110.8M |
| YoY Change | -25.64% | -41.14% | -26.37% |
Cashflow Statement
| Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$7.324M | -$8.113M | -$13.96M |
| YoY Change | -75.52% | -41.9% | 16.15% |
| Depreciation, Depletion And Amortization | $10.00K | $0.00 | $0.00 |
| YoY Change | 0.0% | ||
| Cash From Operating Activities | -$7.160M | -$9.870M | -$9.520M |
| YoY Change | -49.51% | 3.68% | -4.61% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $3.000M | $19.58M |
| YoY Change | -100.0% | -84.68% | -33.63% |
| Cash From Investing Activities | $0.00 | $3.000M | $19.58M |
| YoY Change | -100.0% | -84.68% | -33.63% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | 7.140M | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -7.160M | -9.870M | -9.520M |
| Cash From Investing Activities | 0.000 | 3.000M | 19.58M |
| Cash From Financing Activities | 0.000 | 7.140M | 0.000 |
| Net Change In Cash | -7.160M | 270.0K | 10.06M |
| YoY Change | -56.61% | -97.32% | -45.94% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$7.160M | -$9.870M | -$9.520M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
| dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
| dei |
Entity File Number
EntityFileNumber
|
001-36517 | ||
| dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
| dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1601 Trapelo Road | ||
| dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 286 | ||
| dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Waltham | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
| dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02451 | ||
| dei |
City Area Code
CityAreaCode
|
617 | ||
| dei |
Local Phone Number
LocalPhoneNumber
|
600-7373 | ||
| dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
| CY2020Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
42674491 | |
| CY2020Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q3 | us-gaap |
Liabilities
Liabilities
|
7197807 | |
| CY2020Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
100000000 | |
| CY2020Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42674491 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42674491 | |
| CY2020Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
4267 | |
| CY2020Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
335489256 | |
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-277470620 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58022903 | |
| CY2020Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
65220710 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8112613 | |
| CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41917923 | |
| CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.19 | |
| CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41917923 | |
| CY2019Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.23 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.08 | ||
| CY2019Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39025471 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
40199196 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39006561 | ||
| CY2019Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.23 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.08 | ||
| CY2019Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39025471 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | |
| us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
41175600 | ||
| us-gaap |
Revenues
Revenues
|
41175600 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13897497 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
43497616 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-43497616 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-17797 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1249739 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
40477801 | ||
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
525000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2461699 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15827200 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
77424268 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39006561 | ||
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2221189 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13962003 | |
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
55527375 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27779543 | |
| us-gaap |
Amortization Of Leased Asset
AmortizationOfLeasedAsset
|
106600 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7739704 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7003280 | ||
| nerv |
Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
|
1191811 | ||
| nerv |
Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
|
-529112 | ||
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
797629 | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1615419 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3530784 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
396747 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2588818 | ||
| nerv |
Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
|
-15945 | ||
| nerv |
Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
|
31631 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-41175600 | ||
| nerv |
Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
|
-111229 | ||
| nerv |
Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
|
-127175 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26663142 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-29251354 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
28400000 | ||
| CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5178460 | |
| CY2020Q2 | nerv |
Adjustments To Additional Paid In Capital Costs Earnings Related To Stock Issuance
AdjustmentsToAdditionalPaidInCapitalCostsEarningsRelatedToStockIssuance
|
-219517 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
346026 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3485482 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
29529376 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
56944021 | |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
7371609 | |
| CY2020Q3 | nerv |
Adjustments To Additional Paid In Capital Costs Earnings Related To Stock Issuance
AdjustmentsToAdditionalPaidInCapitalCostsEarningsRelatedToStockIssuance
|
-236149 | |
| CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2056035 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8112613 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58022903 | |
| us-gaap |
Profit Loss
ProfitLoss
|
9265598 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-42265674 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13100 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13100 | ||
| us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
86774 | ||
| us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
661830 | ||
| us-gaap |
Amortization Of Leased Asset
AmortizationOfLeasedAsset
|
118487 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
65845000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3871706 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
49447545 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
24528294 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
16397455 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
12550069 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
455666 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1143655 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
525000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
13238058 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
525000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11103210 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-12328899 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
21512623 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
50334871 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
32615833 | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
38005972 | |
| CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32515833 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26700000 | ||
| CY2020Q3 | nerv |
Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
|
32600000 | |
| CY2019Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
37905972 | |
| CY2020Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2019Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
32615833 | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
38005972 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of Operations </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minerva Neurosciences, Inc. (“Minerva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The Company’s lead product candidate is roluperidone (also known as MIN-101), a compound the Company is developing for the treatment of negative symptoms in patients with schizophrenia, and MIN-301, a compound the Company is developing for the treatment of Parkinson’s disease. In addition, the Company possesses a potential royalty stream from seltorexant (also known as MIN-202 or JNJ-42847922), a compound that is being developed by Janssen Pharmaceutica NV (“Janssen”) for the treatment of insomnia disorder and major depressive disorder (“MDD”).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2013, the Company merged with Sonkei Pharmaceuticals Inc. (“Sonkei”), a clinical-stage biopharmaceutical company and, in February 2014, the Company acquired Mind-NRG, a pre-clinical-stage biopharmaceutical company. The Company refers to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. The Company holds licenses to roluperidone and MIN-117 from Mitsubishi Tanabe Pharma Corporation (“MTPC”) with the rights to develop, sell and import roluperidone and MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, the Company obtained exclusive rights to develop and commercialize MIN-301. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations in each year since inception. As of September 30, 2020, the Company has an accumulated deficit of approximately <span style="color:#000000;">$277.5</span><span style="font-size:12pt;"> </span><span style="color:#000000;">million </span>and net cash used in operating activities was approximately $26.7 million during the nine months ended September 30, 2020. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its operations to date from proceeds from the sale of common stock, warrants, loans and convertible promissory notes.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the Company had cash, cash equivalents, and restricted cash of $32.6 million. <span style="color:#000000;">The Company believes that its existing cash, cash equivalents, and restricted cash will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. As a result of the roluperidone Phase 3 study not achieving a statistically significant improvement on its primary and secondary endpoints, we have significantly decreased our operating plan spending levels. We plan to maintain the lower level of spending while we are preparing for our Type C meeting with the U.S. Food and Drug Administration (“FDA”) in mid-November 2020 to discuss the potential next steps in the development and regulatory approval of roluperidone. Therefore, the year-to-date cash used is not representative of the future cash commitments and spending for the next 12 months after the date that the interim condensed financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs, the infrastructure to support a commercial enterprise, the cost of a commercial product launch, and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials, which will be predicated upon adequate funding to complete the trials. During the nine months ended September 30, 2020, the Company issued and sold 3,381,608 shares of the Company's common stock under the Open Market Sale Agreement (the “Sales Agreement”) with Jefferies, LLC (“Jefferies”). The shares were sold at an average price of $3.7113 per share for aggregate net proceeds to the Company of approximately $12.1 million, after deducting sales commissions and offering costs payable by the Company.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.</p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Risks and Uncertainties</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s business could be adversely affected by the effects of the ongoing COVID-19 pandemic, which continues to have a negative impact on the local, regional, national and global scale. In response to the<span style="font-size:12pt;"> </span>pandemic, a number of jurisdictions in which the Company or its service providers operate implemented shelter-in-place or similar type restrictions, which limited on-site activity to certain service providers. Additionally, the Company’s headquarters are located in Massachusetts, which implemented such restrictions. In response, the Company implemented work-from-home policies for its employees, which continue to be in effect. While certain jurisdictions, including Massachusetts, have begun a phased re-opening of businesses and governmental agencies, there remain limitations on the physical operations of businesses and prohibitions on certain non-essential gatherings, and it is unclear if such phased re-openings will continue or be rolled back, and there is uncertainty about when, if, or how the Company’s workforce may return. The effects of the state executive order, local shelter-in-place orders, government-imposed quarantines and the Company’s work-from-home policies, including the uncertainty about their duration, may negatively impact productivity, disrupt our business and delay the clinical programs and timelines. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the COVID-19 pandemic has not had a material adverse impact on the Company’s operations to date, this disruption, if sustained or recurrent, could have a material adverse effect on the Company’s operating results, its ability to raise capital needed to develop and commercialize products and the Company’s overall financial condition. In addition, a recession or market correction resulting from the spread of the coronavirus could materially affect the value of the Company’s common stock. The impact of the COVID-19 pandemic may also exacerbate other risks discussed in this Quarterly Report on Form 10-Q. Refer to Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q for a complete description of the material risks that the Company currently faces.</p> | ||
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-277500000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p> | ||
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | ||
| CY2020Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2019Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2019Q4 | us-gaap |
Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
|
24441520 | |
| CY2019Q4 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
24442274 | |
| CY2019Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
436 | |
| CY2019Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
1190 | |
| CY2019Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
24441520 | |
| CY2019 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
19000000.0 | |
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | ||
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
Concentration of credit risk <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents </p> <p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p> | ||
| us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P3Y | ||
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | ||
| CY2019Q4 | nerv |
Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
|
3824950 | |
| CY2020Q3 | nerv |
Accrued Severance Current
AccruedSeveranceCurrent
|
49386 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2020Q3 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
1200633 | |
| CY2020Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
66049 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
314213 | |
| CY2020Q3 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
111448 | |
| CY2020Q3 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4535910 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4139163 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8112613 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13962003 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
9265598 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-42265674 | ||
| CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41917923 | |
| CY2019Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39025471 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
40199196 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39006561 | ||
| us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
278605 | ||
| CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41917923 | |
| CY2019Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39025471 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
40477801 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39006561 | ||
| CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2019Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.23 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.08 | ||
| CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.19 | |
| CY2019Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.23 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.08 | ||
| CY2015Q1 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
200000 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.32 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
900000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
|
61000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
|
0 | ||
| CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2056035 | |
| CY2019Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2221189 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7739704 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7003280 |
